Australia: The TGA Gets Set to Get Tough: Likely New Enforcement Options

Last Updated: 29 November 2005
Article by Amanda Turnill

Key Point

  • The TGA's enforcement options will be amplified with the introduction of a tiered regime of criminal offences and civil penalty provisions.

On 17 August 2005 the Therapeutic Goods Amendment Bill 2005 ("the Bill") was introduced into the Federal Parliament.

In May 2003, the Therapeutic Goods Act 1989 ("the Act") was amended to improve regulatory compliance in the wake of the Pan Pharmaceuticals recall. Despite these amendments, there are still perceived inadequacies in the ability of the Therapeutic Goods Administration ("TGA") to address continuing non-compliance by some manufacturers.

The Bill proposes to amplify significantly the enforcement options available to the TGA under the Act by introducing a tiered regime of criminal offences and civil penalty provisions. To enable the more flexible enforcement of these provisions, the TGA will be able to issue infringement notices and accept enforceable undertakings.

Other proposed amendments include extending liability to executive officers and overseas conduct, increasing powers under warrants and expanding the TGA's power to release information.

This article explores and discusses the proposed amendments.

Tiered regime of criminal offences

The Bill proposes to introduce a tiered regime of criminal offences to ensure that serious offences resulting in or likely to cause harm or injury will attract appropriate sanctions. This new regime supplements the existing criminal offences and comprises:

  • a new fault-based offence with an aggravating element (for conduct that results in or will result in harm) attracting a maximum penalty of $440,000 for corporations or individuals and/or five years imprisonment for individuals;
  • a new strict liability offence with an aggravating element (for conduct likely to result in harm) attracting a maximum penalty of $220,000 for corporations or individuals but no term of imprisonment; or
  • the existing fault-based offence with no aggravating element, which will be retained either as it is or with an increased penalty, where appropriate.

The introduction of strict liability offences is designed to act as a strong deterrent to conduct that could threaten the public's health and safety. Strict liability will apply in relation to the most important regulatory requirements, such as those relating to:

  • compliance with applicable standards for therapeutic goods and exemptions granted in relation to the need to comply with such standards;
  • the inclusion of goods in the Australian Register of Therapeutic Goods ("the Register");
  • compliance with conditions applying to inclusion of goods in the Register and conditions attaching to exemptions granted in relation to the need to include goods in the Register;
  • the provision of information that is not false or misleading in a material particular in connection with applications to include goods in the Register; and
  • compliance with manufacturing standards and conditions attaching to manufacturing licences.

When a strict liability provision is breached and that breach is likely to result in harm or injury to any person, criminal sanctions will apply regardless of any mental element. This is similar in application to the strict liability offences created under the consumer protection provisions in Part V of the Trade Practices Act 1974.

The existing fault-based provisions cover intentional or reckless non-compliance with the Act. The new fault-based provisions cover circumstances where the conduct is intentional or reckless and is likely to cause harm, ie where there is a so-called "aggravating element". These new fault-based provisions have higher maximum penalties, which reflects that these offences are regarded as posing a serious and direct threat to public health and safety.

Alternative verdicts from criminal offences

The Bill provides for alternative verdicts for the various tiered offences. If a jury acquits a person of an offence specifying an aggravating element, this proposal would allow them to convict the person of a lesser offence.

The Government has said that the alternative verdict approach is necessary because the tiered regime creates different offences which comprise the same necessary elements. There are similar alternative verdict provisions in other Commonwealth legislation.

Notice requirements for exceptions to criminal offences

The Bill proposes to create an exception to the aggravated fault-based offence of importation, exportation, supply or manufacture of therapeutic goods and medical devices that are not included in the Register and which result in, or will result in, harm. The exception applies if the harm does not or will not result from:

  • the quality, safety or performance of the therapeutic good or medical device;
  • a matter relating to the labelling or packaging of the therapeutic good or medical device; or
  • the improper use of the therapeutic good or medical device.

If a defendant has been committed to be summarily tried for this offence, and the defendant chooses to rely on this exception, the defendant must provide the Director of Public Prosecutions with a notice of the particulars of the exception. This notice must include the name and address of any person that the defendant intends to call to give evidence in support of the exception. The defendant must provide this notice 21 days before the trial or hearing begins.

Civil penalty provisions

In addition to the criminal sanctions, the Bill will also introduce civil penalty sanctions for certain existing offences. These provisions will impose a maximum penalty of $330,000 or $550,000 for an individual, and $3,300,000 or $5,500,000 for a corporation. They are imposed through civil proceedings, not criminal prosecution.

This civil penalty scheme is intended to supplement the TGA's enforcement options so that it can more quickly and efficiently address and deter non-compliance. Civil penalty systems form part of other Commonwealth legislation and are used as an enforcement method by the Australian Competition and Consumer Commission ("ACCC") and the Australian Securities Investment Commission ("ASIC").

The Government has said that these civil penalties are primarily aimed at ensuring compliance by corporate entities. The penalties that will attach to these sections are consequently high so to provide a sufficient deterrent to the corporate sector.

There is a safeguard in the Bill to prevent double jeopardy or multiple punishments for the same conduct. If a person has been convicted of a criminal offence, the proceedings for a civil penalty contravention will be dismissed.

New warrant mechanisms for civil penalty provisions

A new warrant mechanism is included in the Bill to facilitate investigations into civil penalty contraventions. A magistrate can issue a civil penalty warrant if they are satisfied that there are reasonable grounds for suspecting that there is, or that there may be within the next 72 hours, in or on the premises, evidential material in respect of the contravention of a civil penalty provision.

The Bill also increases the powers of authorised persons under search warrants. These powers will enable additional evidence to be secured where the person believes on reasonable grounds that it is evidence of a civil penalty breach (or suspected breach) and that the evidence would be lost, destroyed or concealed unless it is secured.

Infringement notices

The Bill proposes to introduce infringement notices as an alternative to criminal prosecutions or the commencement of civil penalty proceedings. This proposal is an acknowledgment that a lengthy prosecution process or civil proceedings may not be the best way of dealing with some breaches.

Infringement notices may be issued in relation to strict liability offences and civil penalty provisions where easily assessable elements of the breach are present. The person issued with the notice will be given the option of paying the penalty detailed in the notice or have the matter dealt with by a court. If the fine is paid on time, no further liability will arise.

Enforceable undertakings

Another more rapid enforcement method introduced by the Bill is the enforceable undertaking. It is proposed that the Secretary of the Department of Health and Ageing (the department responsible for the TGA) will be able to accept enforceable undertakings as a means of securing compliance with the Act.

Those in breach of the Act will be able to provide an undertaking to correct, address or remedy non-compliance as an alternative to having sanctions imposed. A party in breach will not be able to be compelled to give such an undertaking and the Secretary will not have to accept one. However, once undertakings are accepted, they will become enforceable by the Federal Court of Australia.

It is proposed that details of undertakings given will be published on the internet. The ACCC and ASIC also use undertakings as a method of enforcement, and make these enforceable undertakings available to the public.

Liability for executive officers

If the body corporate commits an offence or breaches a civil penalty provision, executive officers of the body corporate may also incur liability under the Bill.

An executive officer will commit an offence or breach a civil penalty provision if they knew that the offence or breach would be committed, they were in a position to influence the conduct of the body corporate regarding that offence or breach and they failed to take all reasonable steps to prevent its commission. The meaning of executive officer is not limited to a director; it is a person who is concerned in, or takes part in, the management of the business.

The Bill prescribes factors to which the court must have regard in determining whether an executive officer has failed to take reasonable steps to prevent the commission of an offence or breach. These are:

  • what action the officer took to ensure employees, agents and contractors had a reasonable knowledge and understanding of requirements to comply with the Act; and
  • what action the officer took once they became aware that the body corporate was contravening the Act.

The maximum penalty the executive officer could face under these new provisions is the maximum penalty a court could impose on an individual for the relevant offence or breach committed by the body corporate. For example, the maximum penalty for a fault-based offence with an aggravating element is $440,000 and/or five years imprisonment.

Liability for overseas conduct

The Bill proposes to extend the reach of the Act to cover certain overseas conduct by Australian citizens or Australian corporations. The conduct regulated by these new extraterritorial provisions relate to:

  • making false and misleading statements, in a material particular, in connection with an application to include therapeutic goods in the Register;
  • the manufacture, supply, export or import of counterfeit therapeutic goods;
  • the manufacture or supply of tampered goods; and
  • the failure to notify the Secretary of the Department of Health and Ageing or the National Manager of the TGA about actual or potential tampering of therapeutic goods.

Greater power to release information to the public

A lack of transparency and timely release of information was a major criticism of the TGA's actions in relation to Pan Pharmaceuticals. To address this criticism, and generally improve the TGA's ability to protect public health and safety, the Bill proposes to extend the circumstances in which information about actions taken or decisions made under the Act can be released to the public.

There is also increased scope for information about an offence or contravention (actual or alleged) to be released to Australian and overseas regulatory agencies.


These numerous proposals have been designed to give the TGA more power to prevent non-compliance and ensure that public health and safety is protected. The amendments are significant, but their effect in current proposed form may be short-lived. On or about 1 July 2006, the trans-Tasman agency is due to be established. This agency will replace Australia's TGA and New Zealand's Medicines and Medical Devices Safety Authority. It is reasonable to expect that the strengthened enforcement regime proposed by this Bill will be transferred to the new joint Australian and New Zealand regulatory environment.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.